About: Oral administration of a single anti-CfaE nanobody provides broadly cross-protective immunity against major pathogenic Enterotoxigenic Escherichia coli strains

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Oral administration of a single anti-CfaE nanobody provides broadly cross-protective immunity against major pathogenic Enterotoxigenic Escherichia coli strains Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Oral administration of a single anti-CfaE nanobody provides broadly cross-protective immunity against major pathogenic Enterotoxigenic Escherichia coli strains
Creator	Wang, Yang Li, Qi Wallace, Aaron Schneider, Ryan Cavacini, Lisa Ejemel, Monir Klempner, Mark Kruse, Andrew Pierce, Brian Schiller, Zachary Toomey, Jacqueline Amcheslavsky, Alla Barry, Elieen Giuntini, Serena Heukers, Raimond Mcmahon, Conor Meisinger, Jordan Pondish, Jessica
Source	BioRxiv
abstract	Enterotoxigenic Escherichia coli (ETEC) is estimated to cause approximately 380,000 deaths annually during sporadic or epidemic outbreaks worldwide. There is currently no vaccine licensed to prevent ETEC. Development of prophylaxis against ETEC is challenging due to the vast heterogeneity of the ETEC strains. The discovery of nanobodies has emerged as a successful new biologics in treating mucosal infectious disease as nanobodies can recognize conserved epitopes on hypervariable pathogens. In this study, we performed large screens using immunized llamas and a naïve nanobody yeast display library against adhesins of colonization factors. Cross-protective nanobodies were selected with in vitro activities inhibiting mannose-resistant hemagglutination (MRHA) against all eleven major pathogenic ETEC strains. Oral administration of nanobodies led to significant reduction of bacterial colonization in animals challenged with multiple ETEC strains. Structural analysis revealed novel conserved epitopes as critical structural features for pan-ETEC vaccine design. Two of the lead nanobodies, 2R215 and 1D7, were further engineered as trimer or fused with human IgA Fc-fragments as fusionbodies. Oral administration of the trimers or fusionbodies protected mice from infection at a much lower dose compared to the monomeric format. Importantly, fusionbodies prevented infection as a pre-treatment when administrated 2 hours before ETEC challenge to the animals. Together, our study provides the first proof of concept that oral administration of a single nanobody could confer broad protection against major pathogenic ETEC strains. Technological advances in large-scale manufacturing of biological proteins in plants and microorganisms will make nanobody-based immunotherapy a potent and cost-effective prophylaxis or treatment for ETEC.
has issue date	2020-06-17(xsd:dateTime)
bibo:doi	10.1101/2020.06.16.155465
has license	biorxiv
sha1sum (hex)	3405f44c2d3145ac1f298f65d32e72ce790f93db
schema:url	https://doi.org/10.1101/2020.06.16.155465
resource representing a document's title	Oral administration of a single anti-CfaE nanobody provides broadly cross-protective immunity against major pathogenic Enterotoxigenic Escherichia coli strains
schema:publication	bioRxiv
resource representing a document's body	covid:3405f44c2d3145ac1f298f65d32e72ce790f93db#body_text
is schema:about of	named entity 'factors' named entity 'immunized' named entity 'heterogeneity' named entity 'licensed' named entity 'immunity' named entity 'LED' named entity 'USING' named entity 'SELECTED' named entity 'VACCINE DESIGN' named entity 'STRUCTURAL ANALYSIS' named entity 'SUCCESSFUL' named entity 'ACTIVITIES' named entity 'IMMUNIZED' named entity 'BACTERIAL COLONIZATION' named entity 'EPIDEMIC' named entity 'REVEALED' covid:arg/3405f44c2d3145ac1f298f65d32e72ce790f93db named entity 'colonization' named entity 'conserved' named entity 'colonization' named entity 'vaccine' named entity 'outbreaks' named entity 'strains' named entity 'Structural analysis' named entity 'screens' named entity 'llamas' named entity 'strains' named entity 'hemagglutination' named entity 'biologics' named entity 'epitopes' named entity 'epidemic' named entity 'mucosal' named entity 'biologics' named entity 'nanobody' named entity 'nanobodies' named entity 'hemagglutination' named entity 'nanobody' named entity 'llama' named entity 'glucose' named entity 'alanines' named entity 'antigens' named entity 'heavy chain' named entity 'homopolymeric' named entity 'nanobodies' named entity 'antibodies' named entity 'chromatography' named entity 'llama' named entity 'IPTG' named entity 'bacteria' named entity 'sequence homology' named entity 'diarrhea' named entity 'watery diarrhea' named entity 'adhesins' named entity 'adhesins' named entity 'Cross-reactive' named entity 'N-terminal' named entity 'diarrhea' named entity 'MRHA' named entity 'kDa' named entity 'subcutaneously' named entity 'adhesins' named entity 'small intestine' named entity 'phage' named entity 'antigen-binding' named entity 'administered orally' named entity 'OD600' named entity 'organ culture'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software